14 results on '"de Klerk, Johannis B."'
Search Results
2. Inherited Metabolic Disorders and the Skin
- Author
-
de Klerk, Johannis B. C., primary and Oranje, Arnold P., additional
- Published
- 2011
- Full Text
- View/download PDF
3. Glutaric aciduria type I: ultrasonographic demonstration of early signs
- Author
-
Forstner, Rosemarie, Hoffmann, Georg F., Gassner, Ingemar, Heideman, Peter, De Klerk, Johannis B. C., Lawrenz-Wolf, Burghard, Doringer, Ernst, Weiß-Wichert, Peter, Tröger, Jochen, Colombo, Jean P., and Plöchl, Engelbert
- Published
- 1999
- Full Text
- View/download PDF
4. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis
- Author
-
Willemsen, Michèl A., Verbeek, Marcel M., Kamsteeg, Erik-Jan, de Rijk-van Andel, Johanneke F., Aeby, Alec, Blau, Nenad, Burlina, Alberto, Donati, Maria A., Geurtz, Ben, Grattan-Smith, Padraic J., Haeussler, Martin, Hoffmann, Georg F., Jung, Hans, de Klerk, Johannis B., van der Knaap, Marjo S., Kok, Fernando, Leuzzi, Vincenzo, de Lonlay, Pascale, Megarbane, Andre, Monaghan, Hugh, Renier, Willy O., Rondot, Pierre, Ryan, Monique M., Seeger, Jürgen, Smeitink, Jan A., Steenbergen-Spanjers, Gerry C., Wassmer, Evangeline, Weschke, Bernhard, Wijburg, Frits A., Wilcken, Bridget, Zafeiriou, Dimitrios I., and Wevers, Ron A.
- Published
- 2010
- Full Text
- View/download PDF
5. Risk stratification by residual enzyme activity after newborn screening for medium-chain acyl-CoA dehyrogenase deficiency: data from a cohort study
- Author
-
Touw Catharina M L, Smit G Peter A, de Vries Maaike, de Klerk Johannis B C, Bosch Annet M, Visser Gepke, Mulder Margot F, Rubio-Gozalbo M, Elvers Bert, Niezen-Koning Klary E, Wanders Ronald J A, Waterham Hans R, Reijngoud Dirk-Jan, and Derks Terry G J
- Subjects
Population newborn screening ,Enzyme ,Genotype ,Prevalence ,Medicine - Abstract
Abstract Background Since the introduction of medium-chain acyl coenzyme A dehydrogenase (MCAD) deficiency in population newborn bloodspot screening (NBS) programs, subjects have been identified with variant ACADM (gene encoding MCAD enzyme) genotypes that have never been identified in clinically ascertained patients. It could be hypothesised that residual MCAD enzyme activity can contribute in risk stratification of subjects with variant ACADM genotypes. Methods We performed a retrospective cohort study of all patients identified upon population NBS for MCAD deficiency in the Netherlands between 2007–2010. Clinical, molecular, and enzymatic data were integrated. Results Eighty-four patients from 76 families were identified. Twenty-two percent of the subjects had a variant ACADM genotype. In patients with classical ACADM genotypes, residual MCAD enzyme activity was significantly lower (median 0%, range 0-8%) when compared to subjects with variant ACADM genotypes (range 0-63%; 4 cases with 0%, remainder 20-63%). Patients with (fatal) neonatal presentations before diagnosis displayed residual MCAD enzyme activities Conclusions Determination of residual MCAD enzyme activity improves our understanding of variant ACADM genotypes and may contribute to risk stratification. Subjects with variant ACADM genotypes and residual MCAD enzyme activities ACADM genotypes. Parental instructions and an emergency regimen will remain principles of the treatment in any type of MCAD deficiency, as the effect of intercurrent illness on residual MCAD enzyme activity remains uncertain. There are, however, arguments in favour of abandoning the general advice to avoid prolonged fasting in subjects with variant ACADM genotypes and >10% residual MCAD enzyme activity.
- Published
- 2012
- Full Text
- View/download PDF
6. Molybdenum cofactor deficiency: Identification of a patient with homozygote mutation in the MOCS3 gene
- Author
-
Huijmans, Jan G. M., primary, Schot, Rachel, additional, de Klerk, Johannis B. C., additional, Williams, Monique, additional, de Coo, René F. M., additional, Duran, Marinus, additional, Verheijen, Frans W., additional, van Slegtenhorst, Marjon, additional, and Mancini, Grazia M. S., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Functional Hyperactivity of Hepatic Glutamate Dehydrogenase as a Cause of the Hyperinsulinism/ Hyperammonemia Syndrome: Effect of Treatment
- Author
-
HUIJMANS, JAN G. M., DURAN, MARINUS, DE KLERK, JOHANNIS B. C., ROVERS, MARINUS J., and SCHOLTE, HANS R.
- Subjects
Hypoglycemia -- Causes of ,Dehydrogenases -- Health aspects - Abstract
Objective. The combination of persistent hyperammonemia and hypoketotic hypoglycemia in infancy presents a diagnostic challenge. Investigation of the possible causes and regulators of the ammonia and glucose disposal may result in a true diagnosis and predict an optimum treatment. Patient. Since the neonatal period, a white girl had been treated for hyperammonemia and postprandial hypoglycemia with intermittent hyperinsulinism. Her blood level of ammonia varied from 100 to 300 [micro]mol/L and was independent of the protein intake. Methods. Enzymes of the urea cycle as well as glutamine synthetase and glutamate dehydrogenase (GDH) were assayed in liver tissue and/or lymphocytes. Results. The activity of hepatic GDH was 874 nmol/ (min [multiplied by] mg protein) (controls: 472-938). Half-maximum inhibition by guanosine triphosphate was reached at a concentration of 3.9 [micro]mol/L (mean control values: .32). The ratio of plasma glutamine/blood ammonia was unusually low. Oral supplements with N-carbamylglutamate resulted in a moderate decrease of the blood level of ammonia. The hyperinsulinism was successfully treated with diazoxide. Conclusion. A continuous conversion of glutamate to 2-oxoglutarate causes a depletion of glutamate needed for the synthesis of N-acetylglutamate, the catalyst of the urea synthesis starting with ammonia. In addition, the shortage of glutamate may lead to an insufficient formation of glutamine by glutamine synthetase. As GDH stimulates the release of insulin, the concomitant hyperinsulinism can be explained. This disorder should be considered in every patient with postprandial hypoglycemia and diet-independent hyperammonemia. Pediatrics 2000;106:596-600; hyperammonemia, hyperinsulinism, plasma glutamine, glutamate dehydrogenase., ABBREVIATIONS. HIHA, hyperinsulinism/hyperammonemia; GDH, glutamate dehydrogenase; GTP, guanosine triphosphate; CG, carbamylglutamate; ADP, adenosine diphosphate; CSF, cerebrospinal fluid. EXPERIENCE AND REASON--Briefly Recorded "In Medicine one must pay attention not to plausible [...]
- Published
- 2000
8. The Natural Course of Infantile Pompe’s Disease: 20 Original Cases Compared With 133 Cases From the Literature
- Author
-
van den Hout, Hannerieke M. P., primary, Hop, Wim, additional, van Diggelen, Otto P., additional, Smeitink, Jan A. M., additional, Smit, G. Peter A., additional, Poll-The, Bwee-Tien T., additional, Bakker, Henk D., additional, Loonen, M. Christa B., additional, de Klerk, Johannis B. C., additional, Reuser, Arnold J. J., additional, and van der Ploeg, Ans T., additional
- Published
- 2003
- Full Text
- View/download PDF
9. Functional Hyperactivity of Hepatic Glutamate Dehydrogenase as a Cause of the Hyperinsulinism/Hyperammonemia Syndrome: Effect of Treatment
- Author
-
Huijmans, Jan G. M., primary, Duran, Marinus, additional, de Klerk, Johannis B. C., additional, Rovers, Marinus J., additional, and Scholte, Hans R., additional
- Published
- 2000
- Full Text
- View/download PDF
10. Peroxisomal d -hydroxyacyl-CoA dehydrogenase deficiency: Resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency
- Author
-
van Grunsven, Elisabeth G., primary, van Berkel, Emanuel, additional, Ijlst, Lodewijk, additional, Vreken, Peter, additional, de Klerk, Johannis B. C., additional, Adamski, Jerzy, additional, Lemonde, Hugh, additional, Clayton, Peter T., additional, Cuebas, Dean A., additional, and Wanders, Ronald J. A., additional
- Published
- 1998
- Full Text
- View/download PDF
11. Genetic basis of hyperlysinemia.
- Author
-
Houten, Sander M., Brinke, Heleen te, Denis, Simone, Ruiter, Jos P. N., Knegt, Alida C., de Klerk, Johannis B. C., Augoustides-Savvopoulou, Persephone, Häberle, Johannes, Baumgartner, Matthias R., Coskun, Turgay, Zschocke, Johannes, Sass, Jörn Oliver, Poll-The, Bwee Tien, Wanders, Ronald J. A., and Duran, Marinus
- Subjects
METABOLIC disorders ,GENETIC disorders ,LYSINE ,MISSENSE mutation ,GENETIC mutation - Abstract
Background: Hyperlysinemia is an autosomal recessive inborn error of L-lysine degradation. To date only one causal mutation in the gene encoding a-aminoadipic semialdehyde synthase has been reported. We aimed to AASS better define the genetic basis of hyperlysinemia. Methods: We collected the clinical, biochemical and molecular data in a cohort of 8 hyperlysinemia patients with distinct neurological features. Results: We found novel causal mutations in in all affected individuals, including 4 missense mutations, AASS 2 deletions and 1 duplication. In two patients originating from one family, the hyperlysinemia was caused by a contiguous gene deletion syndrome affecting and AASS and PTPRZ1 Conclusions: Hyperlysinemia is caused by mutations in AASS and PTPRZ1 hyperlysinemia is generally considered a benign AASS metabolic variant, the more severe neurological disease course in two patients with a contiguous deletion syndrome may be explained by the additional loss of PIPRZ1. Our findings illustrate the importance of detailed PTPRZ1 biochemical and genetic studies in any hyperlysinemia patient. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Risk stratification by residual enzyme activity after newborn screening for medium-chain acyl-CoA dehyrogenase deficiency: data from a cohort study.
- Author
-
L. Touw, Catharina M., A. Smit, G. Peter, de Vries, Maaike, C. de Klerk, Johannis B., Bosch, Annet M., Visser, Gepke, Mulder, Margot F., Rubio-Gozalbo, M. Estela, Elvers, Bert, Niezen-Koning, Klary E., A. Wanders, Ronald J., Waterham, Hans R., Reijngoud, Dirk-Jan, and J. Derks, Terry G.
- Subjects
DEHYDROGENASES ,GENETIC polymorphisms ,ENZYMES ,PERINATAL growth ,GENETIC research - Abstract
Background: Since the introduction of medium-chain acyl coenzyme A dehydrogenase (MCAD) deficiency in population newborn bloodspot screening (NBS) programs, subjects have been identified with variant ACADM (gene encoding MCAD enzyme) genotypes that have never been identified in clinically ascertained patients. It could be hypothesised that residual MCAD enzyme activity can contribute in risk stratification of subjects with variant ACADM genotypes. Methods: We performed a retrospective cohort study of all patients identified upon population NBS for MCAD deficiency in the Netherlands between 2007-2010. Clinical, molecular, and enzymatic data were integrated. Results: Eighty-four patients from 76 families were identified. Twenty-two percent of the subjects had a variant ACADM genotype. In patients with classical ACADM genotypes, residual MCAD enzyme activity was significantly lower (median 0%, range 0-8%) when compared to subjects with variant ACADM genotypes (range 0-63%; 4 cases with 0%, remainder 20-63%). Patients with (fatal) neonatal presentations before diagnosis displayed residual MCAD enzyme activities <1%. After diagnosis and initiation of treatment, residual MCAD enzyme activities <10% were associated with an increased risk of hypoglycaemia and carnitine supplementation. The prevalence of MCAD deficiency upon screening was 1/8,750 (95% CI 1/7,210-1/11,130). Conclusions: Determination of residual MCAD enzyme activity improves our understanding of variant ACADM genotypes and may contribute to risk stratification. Subjects with variant ACADM genotypes and residual MCAD enzyme activities <10% should be considered to have the same risks as patients with classical ACADM genotypes. Parental instructions and an emergency regimen will remain principles of the treatment in any type of MCAD deficiency, as the effect of intercurrent illness on residual MCAD enzyme activity remains uncertain. There are, however, arguments in favour of abandoning the general advice to avoid prolonged fasting in subjects with variant ACADM genotypes and >10% residual MCAD enzyme activity. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
13. Mutations in PCBD1 cause hypomagnesemia and renal magnesium wasting.
- Author
-
Ferrè S, de Baaij JH, Ferreira P, Germann R, de Klerk JB, Lavrijsen M, van Zeeland F, Venselaar H, Kluijtmans LA, Hoenderop JG, and Bindels RJ
- Subjects
- Adolescent, Animals, Female, HEK293 Cells, Humans, Hydro-Lyases metabolism, Hypercalciuria metabolism, Infant, Kidney Tubules, Distal metabolism, Magnesium metabolism, Male, Mice, Mice, Transgenic, Nephrocalcinosis metabolism, Phenylketonurias genetics, Renal Tubular Transport, Inborn Errors metabolism, Young Adult, Diabetes Mellitus, Type 2 etiology, Hepatocyte Nuclear Factor 1-beta metabolism, Hydro-Lyases genetics, Hypercalciuria genetics, Nephrocalcinosis genetics, Renal Tubular Transport, Inborn Errors genetics, Sodium-Potassium-Exchanging ATPase metabolism
- Abstract
Mutations in PCBD1 are causative for transient neonatal hyperphenylalaninemia and primapterinuria (HPABH4D). Until now, HPABH4D has been regarded as a transient and benign neonatal syndrome without complications in adulthood. In our study of three adult patients with homozygous mutations in the PCBD1 gene, two patients were diagnosed with hypomagnesemia and renal Mg(2+) loss, and two patients developed diabetes with characteristics of maturity onset diabetes of the young (MODY), regardless of serum Mg(2+) levels. Our results suggest that these clinical findings are related to the function of PCBD1 as a dimerization cofactor for the transcription factor HNF1B. Mutations in the HNF1B gene have been shown to cause renal malformations, hypomagnesemia, and MODY. Gene expression studies combined with immunohistochemical analysis in the kidney showed that Pcbd1 is expressed in the distal convoluted tubule (DCT), where Pcbd1 transcript levels are upregulated by a low Mg(2+)-containing diet. Overexpression in a human kidney cell line showed that wild-type PCBD1 binds HNF1B to costimulate the FXYD2 promoter, the activity of which is instrumental in Mg(2+) reabsorption in the DCT. Of seven PCBD1 mutations previously reported in HPABH4D patients, five mutations caused proteolytic instability, leading to reduced FXYD2 promoter activity. Furthermore, cytosolic localization of PCBD1 increased when coexpressed with HNF1B mutants. Overall, our findings establish PCBD1 as a coactivator of the HNF1B-mediated transcription necessary for fine tuning FXYD2 transcription in the DCT and suggest that patients with HPABH4D should be monitored for previously unrecognized late complications, such as hypomagnesemia and MODY diabetes.
- Published
- 2014
- Full Text
- View/download PDF
14. Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients.
- Author
-
Poll-The BT, Gootjes J, Duran M, De Klerk JB, Wenniger-Prick LJ, Admiraal RJ, Waterham HR, Wanders RJ, and Barth PG
- Subjects
- ATPases Associated with Diverse Cellular Activities, Adolescent, Adult, Child, Child, Preschool, Cohort Studies, Developmental Disabilities pathology, Eye Diseases pathology, Face abnormalities, Female, Follow-Up Studies, Growth Disorders pathology, Humans, Infant, Kidney pathology, Liver pathology, Male, Membrane Proteins genetics, Mutation, Peroxisomal Disorders genetics, Peroxisomal Disorders mortality, Phenotype, Seizures pathology, Spleen pathology, Survival Rate, Time Factors, Peroxisomal Disorders pathology
- Abstract
The peroxisome biogenesis disorders (PBDs) with generalized peroxisomal dysfunction include Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD). There is clinical, biochemical, and genetic overlap among the three phenotypes, also known as Zellweger spectrum disorders. Clinical distinctions between the phenotypes are not sharply defined. Only limited sources are available to serve as a background for prognosis in PBD, especially in case of prolonged survival. We delineated the natural history of 31 PBD patients (age 1.2-24 years) through systematic clinical and biochemical investigations. We excluded classical ZS from our study, and included all patients with a biochemically confirmed generalized peroxisomal disorder over 1 year of age, irrespective of the previously diagnosed phenotype. The initial clinical suspicion, age at diagnosis, growth, development, neurological symptoms, organ involvements, and survival are summarized. Common to all patients were cognitive and motor dysfunction, retinopathy, sensorineural hearing impairment, and hepatic involvement. Many patients showed postnatal growth failure, 10 patients displayed hyperoxaluria of whom 4 had renal stones. Motor skills ranged from sitting with support to normal gait. Speech development ranged from non-verbal expression to grammatical speech and comprehensive reading. The neurodevelopmental course was variable with stable course, rapid decline with leukodystrophy, spinocerebellar syndrome, and slow decline over a wide range of faculties as outcome profiles. At the molecular level, 21 patients had mutations in the PEX1 gene. The two most common PEX1 mutations were the G843D (c.2528G-->A) missense and the c.2097insT frameshift mutation. Patients having the G843D/G843D or the G843D/c.2097insT genotypes were compared. Patients homozygous for G843D generally had a better developmental outcome. However, one patient who was homozygous for the "mild" G843D mutation had an early lethal disease, whereas two other patients had a phenotype overlapping with the G843D/c.2097insT group. This indicates that next to the PEX1 genotype other yet unknown factors determine the ultimate phenotype., (Copyright 2004 Wiley-Liss, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.